219 related articles for article (PubMed ID: 27673482)
1. Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors.
Popp TA; Tallant C; Rogers C; Fedorov O; Brennan PE; Müller S; Knapp S; Bracher F
J Med Chem; 2016 Oct; 59(19):8889-8912. PubMed ID: 27673482
[TBL] [Abstract][Full Text] [Related]
2. Recent Advances in the Development of CBP/p300 Bromodomain Inhibitors.
Xiong Y; Zhang M; Li Y
Curr Med Chem; 2020; 27(33):5583-5598. PubMed ID: 31364510
[TBL] [Abstract][Full Text] [Related]
3. Current development of CBP/p300 inhibitors in the last decade.
He ZX; Wei BF; Zhang X; Gong YP; Ma LY; Zhao W
Eur J Med Chem; 2021 Jan; 209():112861. PubMed ID: 33045661
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
[TBL] [Abstract][Full Text] [Related]
5. Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.
Picaud S; Fedorov O; Thanasopoulou A; Leonards K; Jones K; Meier J; Olzscha H; Monteiro O; Martin S; Philpott M; Tumber A; Filippakopoulos P; Yapp C; Wells C; Che KH; Bannister A; Robson S; Kumar U; Parr N; Lee K; Lugo D; Jeffrey P; Taylor S; Vecellio ML; Bountra C; Brennan PE; O'Mahony A; Velichko S; Müller S; Hay D; Daniels DL; Urh M; La Thangue NB; Kouzarides T; Prinjha R; Schwaller J; Knapp S
Cancer Res; 2015 Dec; 75(23):5106-5119. PubMed ID: 26552700
[TBL] [Abstract][Full Text] [Related]
6. Structure-Based Identification of Inhibitory Fragments Targeting the p300/CBP-Associated Factor Bromodomain.
Chaikuad A; Lang S; Brennan PE; Temperini C; Fedorov O; Hollander J; Nachane R; Abell C; Müller S; Siegal G; Knapp S
J Med Chem; 2016 Feb; 59(4):1648-53. PubMed ID: 26731131
[TBL] [Abstract][Full Text] [Related]
7. Modulation of p300/CBP Acetylation of Nucleosomes by Bromodomain Ligand I-CBP112.
Zucconi BE; Luef B; Xu W; Henry RA; Nodelman IM; Bowman GD; Andrews AJ; Cole PA
Biochemistry; 2016 Jul; 55(27):3727-34. PubMed ID: 27332697
[TBL] [Abstract][Full Text] [Related]
8. Combination Targeting of the Bromodomain and Acetyltransferase Active Site of p300/CBP.
Zucconi BE; Makofske JL; Meyers DJ; Hwang Y; Wu M; Kuroda MI; Cole PA
Biochemistry; 2019 Apr; 58(16):2133-2143. PubMed ID: 30924641
[TBL] [Abstract][Full Text] [Related]
9. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator.
Liu X; Wang L; Zhao K; Thompson PR; Hwang Y; Marmorstein R; Cole PA
Nature; 2008 Feb; 451(7180):846-50. PubMed ID: 18273021
[TBL] [Abstract][Full Text] [Related]
10. Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP.
Wu F; Hua Y; Kaochar S; Nie S; Lin YL; Yao Y; Wu J; Wu X; Fu X; Schiff R; Davis CM; Robertson M; Ehli EA; Coarfa C; Mitsiades N; Song Y
J Med Chem; 2020 May; 63(9):4716-4731. PubMed ID: 32314924
[TBL] [Abstract][Full Text] [Related]
11. Structure of the p300 catalytic core and implications for chromatin targeting and HAT regulation.
Delvecchio M; Gaucher J; Aguilar-Gurrieri C; Ortega E; Panne D
Nat Struct Mol Biol; 2013 Sep; 20(9):1040-6. PubMed ID: 23934153
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel CBP bromodomain inhibitors through TR-FRET-based high-throughput screening.
Zhang FC; Sun ZY; Liao LP; Zuo Y; Zhang D; Wang J; Chen YT; Xiao SH; Jiang H; Lu T; Xu P; Yue LY; Du DH; Zhang H; Liu CP; Luo C
Acta Pharmacol Sin; 2020 Feb; 41(2):286-292. PubMed ID: 31253937
[TBL] [Abstract][Full Text] [Related]
13. CBP/p300 Bromodomains Regulate Amyloid-like Protein Aggregation upon Aberrant Lysine Acetylation.
Olzscha H; Fedorov O; Kessler BM; Knapp S; La Thangue NB
Cell Chem Biol; 2017 Jan; 24(1):9-23. PubMed ID: 27989401
[TBL] [Abstract][Full Text] [Related]
14. Unravelling novel congeners from acetyllysine mimicking ligand targeting a lysine acetyltransferase PCAF bromodomain.
Suryanarayanan V; Singh SK
J Biomol Struct Dyn; 2018 Dec; 36(16):4303-4319. PubMed ID: 29228881
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Pyrrolo[3,2- d]pyrimidin-4-one Derivatives as a New Class of Potent and Cell-Active Inhibitors of P300/CBP-Associated Factor Bromodomain.
Huang L; Li H; Li L; Niu L; Seupel R; Wu C; Cheng W; Chen C; Ding B; Brennan PE; Yang S
J Med Chem; 2019 May; 62(9):4526-4542. PubMed ID: 30998845
[TBL] [Abstract][Full Text] [Related]
16. E2A proteins enhance the histone acetyltransferase activity of the transcriptional co-activators CBP and p300.
Hyndman BD; Thompson P; Bayly R; Côté GP; LeBrun DP
Biochim Biophys Acta; 2012 May; 1819(5):446-53. PubMed ID: 22387215
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a Potent, Cell Penetrant, and Selective p300/CBP-Associated Factor (PCAF)/General Control Nonderepressible 5 (GCN5) Bromodomain Chemical Probe.
Humphreys PG; Bamborough P; Chung CW; Craggs PD; Gordon L; Grandi P; Hayhow TG; Hussain J; Jones KL; Lindon M; Michon AM; Renaux JF; Suckling CJ; Tough DF; Prinjha RK
J Med Chem; 2017 Jan; 60(2):695-709. PubMed ID: 28002667
[TBL] [Abstract][Full Text] [Related]
18. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains.
Hay DA; Fedorov O; Martin S; Singleton DC; Tallant C; Wells C; Picaud S; Philpott M; Monteiro OP; Rogers CM; Conway SJ; Rooney TP; Tumber A; Yapp C; Filippakopoulos P; Bunnage ME; Müller S; Knapp S; Schofield CJ; Brennan PE
J Am Chem Soc; 2014 Jul; 136(26):9308-19. PubMed ID: 24946055
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors synergize p300 autoacetylation that regulates its transactivation activity and complex formation.
Stiehl DP; Fath DM; Liang D; Jiang Y; Sang N
Cancer Res; 2007 Mar; 67(5):2256-2264. PubMed ID: 17332356
[TBL] [Abstract][Full Text] [Related]
20. Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation.
Raisner R; Kharbanda S; Jin L; Jeng E; Chan E; Merchant M; Haverty PM; Bainer R; Cheung T; Arnott D; Flynn EM; Romero FA; Magnuson S; Gascoigne KE
Cell Rep; 2018 Aug; 24(7):1722-1729. PubMed ID: 30110629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]